Objectives
Genetic determinants conferring resistance to macrolide, lincosamide, and streptogramin B (MLS
B
) via ribosomal modification such as,
erm
,
msrA/B
and
ereA/B
genes are distributed in bacteria. The main goals of this work were to evaluate the dissemination of MLS
B
resistance phenotypes and genotypes in methicillin-resistant
Staphylococcus aureus
(MRSA) isolates collected from clinical samples.
Methods
A total of 106 MRSA isolates were studied. Isolates were recovered from 3 hospitals in Tehran between May 2016 to July 2017. The prevalence of MLS
B
-resistant strains were determined by D-test, and then M-PCR was performed to identify genes encoding resistance to macrolides, lincosamides, and streptogramins in the tested isolates.
Results
The frequency of constitutive resistance MLS
B
, inducible resistance MLS
B
and MS
B
resistance were 56.2%, 22.9%, and 16.6%, respectively. Of 11 isolates with the inducible resistance MLS
B
phenotype,
ermC
,
ermB
,
ermA
and
ereA
were positive in 81.8%, 63.6%, 54.5% and 18.2% of these isolates, respectively. In isolates with the constitutive resistance MLS
B
phenotype, the prevalence of
ermA
,
ermB
,
ermC
,
msrA
,
msrB
,
ereA
and
ereB
were 25.9%, 18.5%, 44.4%, 0.0%, 0.0%, 11.1% and 0.0%, respectively.
Conclusion
Clindamycin is commonly administered in severe MRSA infections depending upon the antimicrobial susceptibility findings. This study showed that the D-test should be used as an obligatory method in routine disk diffusion assay to detect inducible clindamycin resistance in MRSA so that effective antibiotic treatment can be provided.